Further experience with OK-432 for lymphangiomas.
This study includes all the children treated with OK-432 for lymphangioma at our institute. Twenty-nine children treated between 1999 and 2003 are reported for the first time: twelve cases regressed completely, eight cases regressed more than 50% and seven remained unchanged; two cases were lost at follow-up. The outcome was related to the size of the cysts, the larger ones having a better prognosis. The adverse reactions are discussed and the methods of treatment are described in detail. Fifteen children, treated before 1999 and already reported, are reviewed after a long-term follow-up. Four had a recurrence: one regressed spontaneously and three needed further treatment. The other 11 had no complaints. Even considering the risk of recurrence, OK-432 therapy remains our first line therapy for lymphangiomas, avoiding surgery in most cases.
Luzzatto
C
C
Division of Pediatric Surgery, University of Padua, Via Giustiniani 3, 35128 Padua, Italy. clalupap@hotmail.com
Lo Piccolo
R
R
Fascetti Leon
F
F
Zanon
G F
GF
Toffolutti
T
T
Tregnaghi
A
A
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018191:Lymphangioma, Cystic / Q000188:drug therapy* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D009364:Neoplasm Recurrence, Local; D010844:Picibanil / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D012075:Remission, Spontaneous
D000970:Antineoplastic Agents; D010844:Picibanil